Innexus Biotechnology Stock Net Income
| IXSBFDelisted Stock | USD 0.0001 0.00 0.00% |
Fundamental analysis of InNexus Biotechnology allows traders to better anticipate movements in InNexus Biotechnology's stock price by examining its financial health and performance throughout various phases of its business cycle.
InNexus |
InNexus Biotechnology Company Net Income Analysis
InNexus Biotechnology's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current InNexus Biotechnology Net Income | (6.69 M) |
Most of InNexus Biotechnology's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, InNexus Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, InNexus Biotechnology reported net income of (6.69 Million). This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is notably higher than that of the company.
InNexus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses InNexus Biotechnology's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of InNexus Biotechnology could also be used in its relative valuation, which is a method of valuing InNexus Biotechnology by comparing valuation metrics of similar companies.InNexus Biotechnology is currently under evaluation in net income category among its peers.
InNexus Fundamentals
| Return On Asset | -0.31 | |||
| Current Valuation | 6.69 M | |||
| Shares Outstanding | 163.2 M | |||
| Price To Sales | 17.10 X | |||
| EBITDA | (1.37 M) | |||
| Net Income | (6.69 M) | |||
| Cash And Equivalents | 31.43 K | |||
| Total Debt | 3.36 M | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (1.59 M) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | 79.03 | |||
| Market Capitalization | 114.24 K | |||
| Total Asset | 3.44 M | |||
| Retained Earnings | (33.15 M) | |||
| Net Asset | 3.44 M |
About InNexus Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze InNexus Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of InNexus Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of InNexus Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in InNexus Stock
If you are still planning to invest in InNexus Biotechnology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the InNexus Biotechnology's history and understand the potential risks before investing.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |